- Home
- MUFG vs JNJ Comparison
MUFG vs JNJ Comparison
Compare MUFG & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUFG | JNJ |
|---|---|---|
| Founded | 1880 | 1886 |
| Country | Japan | United States |
| Employees | 178953 | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.0B | 542.4B |
| IPO Year | N/A | 2003 |
Fundamental Metrics
Financial Performance| Metric | MUFG | JNJ |
|---|---|---|
| Price | $20.20 | $254.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $238.20 |
| AVG Volume (30 Days) | 3.2M | ★ 7.7M |
| Earning Date | 05-15-2026 | 04-14-2026 |
| Dividend Yield | 2.32% | ★ 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 2.14 |
| Revenue | N/A | N/A |
| Revenue This Year | $4.62 | $6.63 |
| Revenue Next Year | $10.12 | $7.43 |
| P/E Ratio | ★ $25.47 | $114.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.20 | $151.52 |
| 52 Week High | $21.18 | $251.71 |
Technical Indicators
Market Signals| Indicator | MUFG | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 72.20 |
| Support Level | $19.57 | $233.83 |
| Resistance Level | $21.18 | N/A |
| Average True Range (ATR) | 0.31 | 5.13 |
| MACD | -0.07 | 1.78 |
| Stochastic Oscillator | 40.15 | 99.24 |
Price Performance
Historical ComparisonAbout MUFG Mitsubishi UFJ Financial Group Inc.
Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.